New mRNA tech targets stubborn autoimmune diseases
NCT ID NCT07362758
Summary
This early-stage study is testing a new mRNA therapy designed to treat several autoimmune diseases that haven't responded well to other treatments. The therapy uses technology similar to some COVID-19 vaccines to deliver instructions that target a specific part of the immune system (CD19). Researchers will enroll about 47 patients to first check if the treatment is safe and to find the right dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.